Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sotera Health Company (SHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sotera Health is a Nasdaq-listed provider of mission-critical sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses.
Investors can review Form 8-K filings that report material events such as quarterly financial results, secondary offerings of common stock by selling stockholders, amendments to credit agreements and settlements of specific legal matters. For example, recent 8-Ks describe secondary offerings in which affiliates of Warburg Pincus LLC and GTCR LLC sold shares of SHC, with the company noting that it did not receive proceeds from those sales. Other 8-Ks outline amendments to a first lien credit agreement and the terms of repriced term loans maturing in 2031.
Filings also discuss legal and regulatory developments, including a binding term sheet to resolve a defined group of ethylene oxide claims related to a former Sterigenics facility, and broader risk factors associated with EO and Co-60, regulatory compliance, international operations and leverage. These disclosures help readers understand the legal, operational and financial context around Sotera Health’s sterilization and lab testing activities.
On Stock Titan, users can track new SHC filings as they appear on EDGAR and use AI-powered summaries to interpret complex documents. This includes understanding the implications of current reports on Form 8-K, as well as locating annual and quarterly reports when they are filed, to see segment information for Sterigenics, Nordion and Nelson Labs, capital structure details and updated risk factor discussions.
GTCR Reporting Persons filed Amendment No. 6 to a Schedule 13G/A reporting shared voting power over 31,838,253 shares of Sotera Health Co. That amount represents approximately 11.2% of the 284,392,079 shares outstanding as of February 17, 2026, per the issuer's prospectus supplement.
The filing states the GTCR investors and the Warburg Pincus investors are party to a Stockholders Agreement covering governance and voting arrangements; the filing also notes that GTCR expressly disclaims beneficial ownership of shares owned of record by the Warburg Pincus investors. The filing is a joint disclosure by several GTCR entities, with signatures by Jeffrey Wright.
GTCR-affiliated funds associated with Sotera Health Co completed a large insider sale of Common Stock. On March 6, 2026, the GTCR XI Funds sold 10,000,000 shares of Sotera Health Common Stock in an underwritten public secondary offering at $15.27 per share.
After this transaction, the GTCR XI Funds collectively hold 12,735,301 shares, including 10,107,727 shares held by GTCR Fund XI/A LP, 2,546,564 shares held by GTCR Fund XI/C LP, and 81,010 shares held by GTCR Co-Invest XI LP. These holdings reflect a continued, but reduced, indirect ownership stake by the GTCR entities.
Sotera Health Company disclosed that certain existing stockholders entered into an underwriting agreement with Wells Fargo Securities, LLC to sell 25,000,000 shares of Sotera’s common stock. The shares were priced at $15.270 per share and were sold to the underwriter on March 6, 2026.
The company itself did not issue or sell any common stock in this transaction and will not receive any proceeds from the sale. None of Sotera Health’s executive officers took part as sellers in this offering. The filing also includes the full underwriting agreement and a related legal opinion as exhibits.
Sotera Health Company is registering 25,000,000 shares for resale by selling stockholders. The prospectus supplement states the underwriter has agreed to purchase the shares from the selling stockholders at $15.27 per share, which would yield $381,750,000 to those selling stockholders before expenses, and the Company will not receive proceeds from these sales.
The supplement lists delivery expected on March 6, 2026, notes a Nasdaq last reported sale price of $15.76 per share on March 4, 2026, and describes the underwriter’s ability to sell the shares on Nasdaq, OTC markets or through negotiated transactions.
Sotera Health Co Chairman & CEO Michael B. Petras Jr. reported multiple equity compensation transactions dated March 2, 2026. He exercised 89,686 performance-based share appreciation units (SAUs) granted in 2025 into the same number of common shares and received new awards of 240,248 restricted stock units (RSUs) and 120,124 SAUs under the 2020 Incentive Plan. Several blocks of common stock were withheld at $15.91 per share to cover tax liabilities upon vesting of earlier RSU and SAU awards, rather than sold in the open market. Following these transactions, he directly owned 692,427 common shares and indirectly held 4,819,393 shares through a grantor trust.
Sotera Health Co SVP, General Counsel and Secretary Alexander Dimitrief reported equity award activity tied to restricted stock units and performance-based RSUs. On March 2, 2026, 16,816 performance-based RSUs converted into the same number of common shares following achievement of performance conditions, and related RSU grants from 2024 and 2025 partially vested.
To cover tax withholding obligations on these vestings, the issuer withheld 7,941 and 23,619 shares of common stock at a price of $15.91 per share, reported as tax-withholding dispositions rather than open-market sales. After these transactions, Dimitrief directly held 319,981 shares of common stock and 11,210 performance RSUs, with remaining additional RSUs scheduled to vest in March 2027 and March 2028, subject to performance conditions.
Sotera Health Co Senior Vice President and CFO Jonathan M. Lyons reported multiple equity-related transactions on March 2, 2026. Performance-based RSUs vested and were exercised into Common Stock, and he also received new RSU and performance-based RSU awards under the 2020 Omnibus Incentive Plan.
To cover tax withholding obligations from these vestings, the company withheld shares of Common Stock at $15.91 per share. After these awards, exercises, and tax-withholding dispositions, Lyons continued to hold a substantial number of Sotera Health common shares directly.
Sotera Health Co President of Sterigenics Michael P. Rutz reported multiple equity compensation transactions involving performance-based RSUs and common stock. On March 2, 2026, 14,573 performance RSUs were exercised into the same number of common shares, and 22,612 new performance RSUs were granted at no cash cost.
On the same date, he received a grant of 45,223 shares of common stock, and several blocks of common shares (3,729, 4,495, and 17,497 shares at $15.9100 per share) were disposed of to cover tax withholding tied to vesting RSU awards. Following these transactions, he directly held 484,279 shares of common stock and 22,612 performance RSUs, with additional RSUs and performance-based RSUs subject to future vesting and performance conditions under the 2020 Omnibus Incentive Plan.
Sotera Health Company discloses a resale offering by certain selling stockholders pursuant to a preliminary prospectus supplement dated March 4, 2026.
The company states it is not selling any shares in this filing and will receive no proceeds from the shares sold by the selling stockholders; proceeds will go to those selling holders. The prospectus cites 284,392,079 shares outstanding as of February 17, 2026 and a last reported Nasdaq sale price of $15.76 per share on March 4, 2026.
Sotera Health Company provides mission-critical sterilization, lab testing and advisory services to global medical device, pharmaceutical, food and advanced materials customers. It operates 62 facilities in 13 countries with over 3,000 employees, serving more than 40 of the top 50 medical device makers and nine of the top ten global pharmaceutical companies.
Through Sterigenics and Nordion, Sotera offers gamma, ethylene oxide (EO), E‑beam and emerging X‑ray and NO₂ sterilization, and supplies Co‑60 under multi‑year reactor contracts that run as far as 2064. Nelson Labs adds over 900 microbiology and analytical chemistry tests and expert advisory services across the product lifecycle.
The company highlights heavy regulation and evolving EO and radiation standards, including new U.S. EPA NESHAP and FIFRA rules and planned environmental capital expenditures of about $51 million in 2026. It also faces significant EO‑related tort litigation and has entered into settlements totaling hundreds of millions of dollars, while additional claims remain pending.